Evidence map›Paper›PMID 37576880›Full record

ArticleFrontiers in oncology2023

U-CHANGE Project: a multidimensional consensus on how clinicians, patients and caregivers may approach together the new urothelial cancer scenario.

Sergio Bracarda, Roberto Iacovelli, Valentina Baldazzi, Paolo Andrea Zucali, Angela Gernone, Giario Natale Conti, Giovanni Pappagallo, Matteo Brunelli, Paolo Bruzzi, Edoardo Fiorini and 16 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Sergio BracardaPresident of Italian Society of Uro-Oncology, Department of Medical Oncology, Santa Maria Hospital, Terni, Italy.
Roberto IacovelliDepartment of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Valentina BaldazziDepartment of Medical Oncology, Santa Maria Annunziata Hospital, Florence, Italy.
Paolo Andrea ZucaliDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Angela GernoneDepartment of Medical Oncology, Policlinico Universitario Azienda Ospedaliera (A.O), Bari, Italy.
Giario Natale ContiItalian Society of Uro-Oncology, Bologna, Italy.
Giovanni PappagalloItalian Society of Uro-Oncology, Bologna, Italy.
Matteo BrunelliPathology Unit, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Paolo BruzziDepartment of Clinical Epidemiology, National Institute for Cancer Research, Istituto Scientifico Tumori (IST), Genoa, Italy.
Edoardo FioriniPaLiNUro Association, Milan, Italy.
Laura MagentaPaLiNUro Association, Milan, Italy.
Francesco DiomedeFederazione Associazioni Volontariato in Oncologia (F.A.V.O) Federation, Rome, Italy.
Federico MeretaScientific Journalist, Freelance, Milan, Italy.
Irma D'AriaJournalist, Medikea TV, Rome, Italy.
Danilo MaglianoJournalist, Pharmastar, Milan, Italy.
Monica LiberatoriDepartment of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Daniela CantùItalian Association of Physiotherapists, Milan, Italy.
Davide CroceCentro di Ricerca sull'Economia e il Management in Sanità e nel Sociale, Libero Istituto Universitario Cattaneo (LIUC) Business School, Castellanza (VA), Turin, Italy.
Simone EandiSocial Innovation EcosystEm Development (SEEd) Medica Publishers, Turin, Italy.
Giorgio Lorenzo ColomboStudi Analisi Valutazioni Economiche (SAVE) Institute, Milan, Italy.
Fulvio FerranteDepartment of Diagnostic and Pharmaceutical Assistance, Unità Operativa Complessa (UOC) Pharmacy, Local Health Unit Azienda Sanitaria Locale (ASL) Frosinone, Frosinone, Italy.
Emanuela Omodeo SalèDepartment Hospital Pharmacy, European Institute of Oncology (IEO), Milan, Italy.
Andrea MarinozziClinical Pharmacy, Azienda Ospedaliera Universitaria (AOU) Ospedali Riuniti, Ancona, Italy.
Daniele LenziMedical Department, Azienda Ospedaliera Università, Siena, Italy.
Francesca RemiddiMedical Writing & Statistics Department, NUME PLUS, Florence, Italy.
Stefano RemiddiMedical Writing & Statistics Department, NUME PLUS, Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Advanced urothelial carcinoma remains aggressive and very hard to cure, while new treatments will pose a challenge for clinicians and healthcare funding policymakers alike. The U-CHANGE Project aimed to redesign the current model of care for advanced urothelial carcinoma patients to identify limitations ("as is" scenario) and recommend future actions ("to be" scenario). Methods: Twenty-three subject-matter experts, divided into three groups, analyzed the two scenarios as part of a multidimensional consensus process, developing statements for specific domains of the disease, and a simplified Delphi methodology was used to establish consensus among the experts. Results: Recommended actions included increasing awareness of the disease, increased training of healthcare professionals, improvement of screening strategies and care pathways, increased support for patients and caregivers and relevant recommendations from molecular tumor boards when comprehensive genomic profiling has to be provided for appropriate patient selection to Discussion: While the innovative new targeted agents have the potential to significantly alter the clinical approach to this highly aggressive disease, the U-CHANGE Project experience shows that the use of these new agents will require a radical shift in the entire model of care, implementing sustainable changes which anticipate the benefits of future treatments, capable of targeting the right patient with the right agent at different stages of the disease.

Indexed as

advanced urothelial carcinomaDelphi panelmolecular tumor boardmultidimensional consensuspartnershipstakeholders

Identifiers

PMID37576880
PMCPMC10422043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.